secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biomea Fusion, Inc. (BMEA)
CIK:        0001840439
Form:       8-K
Filed at:   2025-01-15T23:59:59+00:00
Accession:  0001193125-25-007107
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biomea Fusion pivots to diabetes & obesity; icovamenib shows 1.5% HbA1c drop in insulin-deficient patients
--------------------------------------------------------------------------------

- Placebo-adjusted 1.5% mean HbA1c reduction in severe insulin-deficient T2D patients after 12 weeks of icovamenib, sustained 14 weeks off treatment.
- Placebo-adjusted 1.0% HbA1c reduction in patients uncontrolled on GLP-1 therapies, consistent with preclinical synergy with semaglutide.
- 100% of severely insulin-deficient patients on 100 mg icovamenib responded with durable HbA1c decline; no drug-related adverse events.
- Company plans to end oncology studies, seek partnerships, and focus on two late-stage trials: Phase 2/3 in insulin-deficient T2D and Phase 2b combo with GLP-1.
- Novel oral menin inhibitor designed to regenerate beta cells; FDA discussions expected to support late-stage development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840439/000119312525007107/0001193125-25-007107-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840439/000119312525007107/d830016d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-007107

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer